FDA grants AT-GAA breakthrough therapy in research to be identified as used to treat late-haired Pompeii disease
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Pompeii disease is a genetic lysosome setic saclic disorder caused by the absence of acid-alpha-glucosinase (GAA)AT-GAA is the first to be identified as Pompeii diseasethe(http:// of theFDArecently, Amicus Therapeuticscompany(http://announced that the U.SFDA has awarded it a therapeutic AT-GAA breakthrough therapy for the treatment of late-night hair-dosicdiseaseon AT-GAAAT-GAA is a combination therapy developed by AmicusIt has two active ingredients, one is ATB200, a unique recombinant human GAA (rhGAA) proteaseIts carbohydrate structure is optimized to enhance the ability to be absorbed by cellsATB200 can replace the function of THE missing GAA in Pompeii patientsanother active ingredient is AT2221, a pharmacological companionGAAs produced by Pompeii patients themselves are usually degraded by a structural mutation The function of AT2221 is to combine with the patient's own GAA to improve their stability and thus maintain gaA levels Amicus is a bio
pharmaceutical (http:// company dedicated to developing innovative treatments for rare diseases
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
